Vimarsana
Biggest News Aggregation in the World

Page 3 - Time Dynamix News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Time Dynamix. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Time Dynamix Today - Breaking & Trending Today

Declining MS Sales for Historic Powerhouse Biogen Point to Shifting Tides in the Multiple Sclerosis Market According to Spherix Global Insights - Vimarsana News

Declining MS Sales for Historic Powerhouse Biogen Point to Shifting Tides in the Multiple Sclerosis Market According to Spherix Global Insights

/PRNewswire/ -- According to Biogen's earnings call on Wednesday, February 15, 2023, sales for its multiple sclerosis (MS) franchise are down for the third...

U.S. Nephrologists Report Mixed Reactions to the Approval of GSK's Jesduvroq® (daprodustat) for the Treatment of Anemia in Dialysis Patients, According to Spherix Global Insights - Vimarsana News

U.S. Nephrologists Report Mixed Reactions to the Approval of GSK's Jesduvroq® (daprodustat) for the Treatment of Anemia in Dialysis Patients, According to Spherix Global Insights

/PRNewswire/ -- Since 2017, Spherix Global Insights has been monitoring the U.S. renal anemia market landscape, capturing nephrologists' perceptions and...

Substantial Changes in Management of Patients with Chronic Kidney Disease as New Treatment Options Such as Bayer's Kerendia and SGLT2 Inhibitors Gain Traction in US and EU Markets - Vimarsana News

Substantial Changes in Management of Patients with Chronic Kidney Disease as New Treatment Options Such as Bayer's Kerendia and SGLT2 Inhibitors Gain Traction in US and EU Markets

/PRNewswire/ -- With SGLT2 inhibitors increasingly becoming the standard of care for diabetic and non-diabetic CKD patients, the broader CKD treatment has...

Long-Term Psoriatic Arthritis Data for AbbVie's Skyrizi Likely to Impact Future IL-23 Preference, Spherix Global Insights Reports - Vimarsana News

Long-Term Psoriatic Arthritis Data for AbbVie's Skyrizi Likely to Impact Future IL-23 Preference, Spherix Global Insights Reports

/PRNewswire/ -- Spherix Global Insights, a leading provider of market research, business intelligence, and advisory services to the global life sciences...

The European Medicines Agency's Updated Guidelines for JAK Inhibitors in Rheumatoid Arthritis - A Cause for Concern? Spherix Investigates - Vimarsana News

The European Medicines Agency's Updated Guidelines for JAK Inhibitors in Rheumatoid Arthritis - A Cause for Concern? Spherix Investigates

/PRNewswire/ -- On October 28, 2022, the European Medicines Agency's (EMA) safety committee (PRAC) announced recommendations to minimize the risk of serious...